ClinicalTrials.gg
CompletedNCT06840535OncoACP-3Updated Jan 6, 2026

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

A Phase 1 interventional study of [68Ga]Ga-OncoACP3 in Prostate Cancer, Prostate Cancer Metastatic Disease and PSA Level Greater Than 0.2, sponsored by Philogen S.p.A.. Completed at 3 sites in Italy. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Gallium-68 in Prostatic Neoplasms — 8 open to participants now, 8 under way, 2 of them phase 3. Gallium-68 · Prostatic Neoplasms.

Enrollment
9th of 11
20 · median 40
Started
2025
the only one that year
Phase 1
6 of 11
4 open now
Registered
4th of 11
by date
Lead sponsor
2 of 11
Philogen S.p.A.

Among the 11 studies testing Gallium-68 in Prostatic Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 6 in phase 1, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 11 studies testing Gallium-68 in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About Gallium-68

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Gallium-68 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to assess the safety and dosimetry of [68Ga]Ga-OncoACP3 in patients with prostate cancer.

Read the detailed description

The Acid Phosphatase 3 (ACP3) is expressed in primary and metastatic prostate cancer lesions. OncoACP3 is a new ligand for ACP3.

This is a phase I, multicenter clinical trial to evaluate the safety, dosimetry and biodistribution of [68Ga]Ga-OncoACP3 as a PET radiotracer for the diagnostic imaging of prostate cancer. In this trial, 68Ga-OncoACP3 is offered to prostate cancer patients who already received standard of care imaging and might therefore complement available modalities.

Eligible patients for this trial are prostate cancer patients, aged 18 years or more with:

  • suspected metastasis who are candidates for initial definitive therapy
  • suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL)
  • metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

All patients will undergo PET/CT imaging with [68Ga]Ga-OncoACP3.

Patients are divided into two cohorts:

  • Cohort A: 5 male patients without visceral or bone metastases, which would interfere with dosimetry evaluation of healthy organs.
  • Cohort B: all patients who meet the eligibility criteria (up to 15 patients)

Both cohorts are recruited in parallel, and patients are assigned to the respective cohort based on their disease extent. Whenever possible, patients are enrolled in cohort A, unless they are unsuitable for cohort A, or the required number of patients has already been enrolled in cohort A.

All patients will receive a single intravenous bolus administration of [68Ga]Ga-OncoACP3 and biodistribution, PK, and dosimetry of [68Ga]Ga-OncoACP3 will be assessed based on a series of PET/CT scans, blood and urine sampling.

Full dosimetry evaluations will be performed for all patients in cohort A. Dosimetry in the other patients may be performed to the extent that it is possible based on their disease burden (i.e., only organs not affected by malignant lesions can be evaluated), as appropriate.

All patients will be assessed for safety. In addition, relative uptake to appropriate reference tissue of [68Ga]Ga-OncoACP3 as well as semiquantitative parameters such as SUVmax/SUVmean/SUVsd, are determined. The correlation of [68Ga]Ga-OncoACP3 uptake with immunopathology staining for ACP3 will be evaluated in patients undergoing surgery or tumor biopsy collection. For patients who undergo PSMA-PET/CT within 4 weeks before or after the [68Ga]Ga-OncoACP3-PET/CT scan, the lesion detection rate will be compared Full dosimetry evaluations will be performed for all patients in cohort A. Additional dosimetry in the other patients may be performed to the extent that it is possible based on their disease burden (i.e., only organs not affected by malignant lesions can be evaluated).

03

Conditions studied

  • Prostate Cancer
  • Prostate Cancer Metastatic Disease
  • PSA Level Greater Than 0.2

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prostate cancer patients with:

    • suspected who are candidates for initial definitive therapy
    • suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL)
    • metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
  2. Patients with a negative PSMA-PET/CT or discordant PSMA PET and FDG-PET findings are eligible for this study, providing that they have a confirmed diagnosis of prostate cancer.
  3. Subjects able to father children must agree to practice effective for three months starting from the study drug administration.
  4. Age ≥ 18
  5. ≤ 1
  6. Patient must not have any concomitant infections or active concomitant disease.
  7. All acute toxic effects (excluding alopecia and fatigue) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) (CTCAE) (v. 5.0) Grade ≤ 1.
  8. of more than 12 weeks.
  9. Ability to undergo imaging study procedures.
  10. Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  11. Willingness and ability to comply with the scheduled visits, plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Chronically impaired renal function as expressed by \< 60 mL/min or serum creatinine > 1.5 x .
  2. Presence of active hepatitis.
  3. Presence of significant cardiac disorders (congestive heart failure, class III-IV, myocardial infarction within one year prior to study entry, uncontrolled hypertension, or arrhythmia).
  4. Any concomitant condition which in the opinion of investigators makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  5. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of the study drug. Minimally invasive procedures such as are not considered as exclusion criteria.
  6. Serious, non-healing wound, ulcer, or bone fracture.
  7. Allergy to study medication or in study medication.
  8. Any anti-cancer therapy (e.g., cytotoxic chemotherapy, immunotherapy, radiation, surgery, etc.) within 3 weeks before [68Ga]Ga-OncoACP3-PET/CT scan.
  9. Subject has received, or is scheduled to receive, another medicinal product (IMP) from one month before [68Ga]Ga-OncoACP3 injection to end of study participation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Coort A

    5 male patients without visceral or bone metastases, which would interfere with dosimetry evaluation of healthy organs.

  • Experimental
    Coort B

    All patients who meet the eligibility criteria (up to 15 patients)

    Drug: [68Ga]Ga-OncoACP3

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort A: Dosimetry - Effective dose equivalent (mSv)

    Whole-body effective dose (mSv) following administration of a single dose of \[68Ga\]Ga-OncoACP3.

    Time frame: Assessed on day 1

  2. Cohort A: Dosimetry - Effective dose absorbed doses (mGy)

    Absorbed doses (mGy) of normal organs following administration of a single dose of \[68Ga\]Ga-OncoACP3.

    Time frame: Assessed on day 1

  3. All patients: Safety (AEs and SAEs)

    Safety of administration of \[68Ga\]Ga-OncoACP3, assessed based on Common Toxicity Criteria (CTCAE version 5.0)

    Time frame: Throughout study, until a maximum of 7 days after the administration of the study drug.

Secondary outcomes

  1. Pharmacokinetics (PK) - Blood

    Pharmacokinetics (PK) of \[68Ga\]Ga-OncoACP3 based on measurement on blood of residual radioactivity over time \[kBq/mL\]

    Time frame: Assessed on day 1

  2. Excretion - Urine

    Excretion of \[68Ga\]Ga-OncoACP3 based on measurement of residual radioactivity in the urine over time \[kBq\]

    Time frame: Assessed on day 1

  3. Biodistribution profile: SUVmax

    Uptake of \[68Ga\]Ga-OncoACP3 in tumor lesions and healthy organs in terms of SUVmax

    Time frame: Assessed on day 1

  4. Biodistribution profile: SUVmean

    Uptake of \[68Ga\]Ga-OncoACP3 in tumor lesions and healthy organs in terms of SUVmean

    Time frame: Assessed on day 1

  5. Biodistribution profile: SUVsd

    Uptake of \[68Ga\]Ga-OncoACP3 in tumor lesions and healthy organs in terms of SUVsd

    Time frame: Assessed on day 1

Other outcomes

  1. Immunopathology staining

    Correlation of the uptake of \[68Ga\]Ga-OncoACP3 with immunopathology staining for ACP3 expression and comparison to staining for PSMA expression, in all patients for whom surgical or biopsy specimen are available.

    Time frame: Within 8 weeks of the scan, surgery and biopsy collection

  2. Lesion detection rate

    Lesion detection rate compared to PSMA-PET/CT.

    Time frame: The [68Ga]Ga-OncoACP3-PET/CT scan needs to be collected within 4 weeks

07

Study locations

3 sites
  • ASST Papa Giovanni XXIII
    Bergamo, BG 24127, Italy
  • IRCCS Ospedale San Raffaele
    Milan, Milano 20132, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Milano 20133, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Oct 2025, 5 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 5 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Feb 21, 2025
StartActual
Apr 8, 2025
Primary completionActual
Oct 3, 2025
CompletionActual
Oct 3, 2025
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06840535
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Apr 8, 2025
Primary completion
Oct 3, 2025
Completion
Oct 3, 2025
Last update
Jan 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion